Abstract. The annual death toll for gastric cancer is in the range of 700,000 worldwide. Even in patients with early-stage gastric cancer recurrence within five years has been observed after surgical resection and following chemotherapy with therapy-resistant features. Therefore, the identification of new targets and treatment modalities for gastric cancer is of paramount importance. In this review we focus on the role of microRNAs with documented efficacy in preclinical xenograft models with respect to growth of human gastric cancer cells. We have identified 31 miRs (-10b, -19a, -19b, -20a, -23a/b, -25, -27a-3p, -92a, -93, -100, -106a, -130a, -135a, -135b-5p, -151-5p, -187, -199-3p, -215, -221-3p, -224, -340a, -382, -421, -425, -487a, -575, -589, -664a-3p) covering 26 different targets which promote growth of gastric cancer cells in vitro and in vivo as xenografts. Five miRs (miRs -10b, 151-5p, -187, 532-3p and -589) additionally have an impact on metastasis. Thirteen of the identified miRs (-19b, -20a/b, -25, -92a, -106a, -135a, -187, -221-3p, -340a, -421, -493, -575 and -589) have clinical impact on worse prognosis in patients.

Gastric cancer (GC) is the third-leading cause of cancer worldwide and is the forth most common cancer with an annual death toll of 700,000 worldwide (1). Intestinal-type and diffuse-type are the major histological subtypes (2). A total of 90% of GCs are adenocarcinomas which arise from the glandular epithelium (1). A total of 1-3% of GCs are hereditary cancers due to inactivating mutations in E-cadherin (1). From a molecular point of view, the following subtypes have been defined: Epstein-Barr-Virus (EBV)-positive with pronounced DNA hypermethylation, genomic stable subtype with distinctive genomic alterations, the microsatellite instability subtype (MSI) and the chromosomal instability (CIN) subtype characterized by aneuploidy and focal amplification of transmembrane receptor tyrosine kinases (3). These subtypes are correlated with different survival and outcomes of chemotherapy (3). Several agents have been approved for the treatment of gastric cancer: chemotherapy-based drugs such as 5-fluorouracil (5-FU)-related agents, docetaxel, doxorubicin and mitomycin B as well as monoclonal antibodies (mAb) such as trastuzumab (HER2 as a target) for HER2-positive patients, ramicurumab (VEGFR2 as a target) and checkpoint-inhibitory antibody pembrolizumab directed against programmed cell death 1 (PD1) (5-10).

Nevertheless, in patients with early-stage GC, recurrence within 5 years after surgical resection and subsequent chemotherapy has been observed (4, 5). The prognosis of patients with advanced GC is significantly worse (4, 5). Therefore, the identification of new targets and treatment modalities is an important issue. In this review, we describe the role of microRNAs (miRs) in pathogenesis and metastasis of GC. We focus on miRs which are up-regulated in GC tissue in comparison to matching normal tissues which exhibit efficacy in preclinical in vivo models. We have excluded: miRs playing a functional role in Helicobacter pylori-related gastric cancer models, miRs exerting their function by interaction with non-coding RNAs, miRs delivered by exosomes and those induced in tumor cells by stromal cells.

Key Words: Apoptosis, migration, invasion, proliferation, clinical prognosis, gastric cancer xenograft models, microRNA targets and inhibitors, tumor growth and metastasis, review.
microRNAs and Their Role in Oncology

miRs are double-stranded non-coding RNAs comprising 22-25 nucleotides (nts) which are generated from precursors transcribed in the nucleus, processed and finally 22-25 nts miR complexes are released into the cytoplasm (12-14). The guide strand is maintained and the other strand, the passenger strand, is degraded (13, 14). A single miR species may repress several miRs and each mRNA can be degraded by several different miRs indicating their potential to modulate several pathways and cellular networks (15). miRs can be transcribed from single transcriptional units or from multicistronic transcripts from a coding gene, introns or non-coding genes (15).

In oncology, miRs function as oncogenes as well as tumor suppressors (TS), depending on the cell-type in which they are expressed (15-17). Genetic deletion of the miR-15/16 genetic locus in mice recapitulated the features of human chronic lymphocytic leukemia, supporting their role as tumor suppressors (18). An oncogenic role was identified for miR-221 which induced hepatocellular carcinomas in transgenic mice after liver-specific expression (19). miRs are also involved in metastasis. We have recently summarized their role in metastasis in breast-, prostate, ovarian, lung and pancreatic cancer (20).

miRs Inhibiting Tumor Suppressors

PTEN. miRs-221-3p (25), -382 (26), -425 (27) and -575 (28) (Figure 1) target phosphatase and tensin homolog PTEN which dephosphorylates phosphatidylinositol-3,4,5 triphosphate and thus negatively regulates the AKT signaling pathway (29, 30). miRs -382 and -425 are induced by hypoxia-inducible factor 1 (HIF-1) or interleukin 1β (IL1β), respectively (26, 27). miRs-221-3p, -382, -425 and -575 affect tumor growth of gastric cancer cell lines SNU-1, MKN1, NCI-N87 and MGC-803 respectively after subcutaneous implantation into nude mice (25-28). miR-382 also affects angiogenesis, by promoting sprouting, branching and network formation of blood vessels induced by vascular endothelial growth factor (VEGF) (26). Overexpression of miRs-221-3p and -575 in GC patients in comparison to matching normal tissues correlates with worse prognosis (25,28). All the discussed miRs activate AKT signaling. Data derived from The Cancer Genome Atlas (TGCA) show that miR-221 is overexpressed in GC tissues in comparison to matching normal tissues correlates with worse prognosis (35). miR-187 promotes tumor growth (TG) after subcutaneous implantation into nude mice and increased lung colonization after tail vein injection (35). Forkhead box protein A2 (FOXA2) was identified as a direct target of miR-187 (35). It was shown that FOXA2 mediates the biological functions of miR-187 (35). FOXA2 is a transcriptional factor which suppresses gastric carcinogenesis in vitro and in vivo (36).

RASSF8. miR-224 (Figure 1) is induced by hypoxia and increases cell viability and invasion in gastric cancer cell lines SGC-7901 and MGC-803 (31). SCG-7901 cells transfected with a miR-224 antagonim exhibit reduced growth after subcutaneous implantation into nude mice (31). Ras-association domain containing protein 8 (RASSF8) was identified as a direct target of miR-224 (32). RASSF8 is a member of a family of 10 genes which are linked to processes such as cell proliferation, cell death and responses to hypoxia (32). The above mentioned in vitro effects were recapitulated by overexpression of RASSF8 in SGC-7901 and MGC-803 cells (31). RASSF8 overexpression inhibits nuclear factor κB (NFκB) signaling and its functions as a TS (33, 34).

microRNAs Targeting Transcription Factors

miR-187 (FOXA2). Increased expression of miR-187 (Figure 1) is associated with clinico-pathological features and prognosis in GC patients (35). miR-187 promotes proliferation, migration and invasion of SGC-7901 GC cells (35). SGC-7901 cells overexpressing miR-18 exhibit increased tumor growth (TG) after subcutaneous implantation into nude mice and increased lung colonization after tail vein injection (35). Forkhead box protein A2 (FOXA2) was identified as a direct target of miR-187 (35). It was shown that FOXA2 mediates the biological functions of miR-187 (35). FOXA2 is a transcriptional factor which suppresses gastric carcinogenesis in vitro and in vivo (36).

miR-199-3p (ZHIX1). miR-199-3p increases proliferation and suppresses apoptosis in vitro and in vivo of GC cell lines SGC-7901 and NCI-N87 (37) (Figure 1). Transcription factor zinc fingers and homeoboxes (ZHIX1) was identified as a target for miR-199-3p (37). Restoring ZHX1 expression in SGC-7901/miR-199-3p cells inhibits cell proliferation induced by miR-199a-3p (37). It has been shown that ZHX1 inhibits GC cell growth through inducing cell-cycle arrest and apoptosis (38). The ZHX family consists of three members containing two Cys2HIs2 zinc finger domains and five homeobox DNA-binding motifs (39).

RUNXI and RUNX3. miRs-215 and -532-3p (Figure 1) target runt-related transcription factors RUNX1 or RUNX3 respectively (40, 41). Ectopic expression of miR-215 promotes migration and invasion of GES-1 and HGC-27 cells (35). RUNX1 could partially reverse the function of miR-215 (35). HGC-27 cells stably expressing miR-215 metastasize to the liver after intraperitoneal injection (40). miR-532-5p promotes growth and migration of BGC-823 gastric cancer cells (36). In vivo miR-532-3p promotes lung colonization after tail vein injection of BCG-823 gastric cancer cells transfected with miR-532-3p (41). The RUNX family of transcription factors are frequently inactivated in cancer and function as TS (42). RUNX1 plays a role in early steps of haematopoesis and acts as a TS in breast cancer (43). RUNX3 was shown to have a tumor- and metastasis suppressive role in GC (44-47).
miRs Targeting Ubiquitin-related Enzymes

miR-25. miR-25 (Figure 3A) is overexpressed in primary tumor tissues of GC patients and is significantly correlated with a more aggressive phenotype of GC in patients (48). miR-25 mediates proliferation, invasion and migration of GC in vitro and promotes TG in vivo (48). F-box/WD repeat containing protein 7 (FBXW7) was identified as a direct target of miR-25 (48). Restauration of expression of FBXW7 led to reversion of the described in vitro effects (48). F-box proteins constitute one of the four subunits of the ubiquitin-protein ligase system (49, 50). FBXW7 has been shown to function as a TS of human tumorigenesis (51). Data from TCGA show that miR-25 is over-expressed in GC tissues in comparison to matching normal tissues (Figure 2).

miR-100. Expression of miR-100 (Figure 3A) correlates with GC tumorigenesis and progression (52). Inhibition of miR-100 results in apoptosis of poorly differentiated gastric cancer cells, but not of non-cancerous gastric cells in vitro and in vivo (52). RNF144B, an E3-ubiquitin ligase was identified as a direct target of miR-100. RNF144B contains a single transmembrane domain close to the C-terminus, is localized in the nucleoli and mitochondria and promotes apoptosis under various cell damaging events by degradation of p53 (53-55).

miRs Targeting Transmembrane Receptors

miR-106a. miR-106a (Figure 3B) expression is significantly associated with tumor size, lymphatic and distant metastasis (56). miR-106 inhibits apoptosis of GC cells AGS, N87 and BGC823 (56, 57). FASR (CD95) and caspase 3 were identified as direct targets of miR-106 (56, 57). MicroRNA-106a functions as an oncogene in human gastric cancer and contributes to proliferation and metastasis in vitro and in vivo. miR-106 inhibits GC cell apoptosis through a FASR (CD95)-mediated, extrinsic cell death pathway (56-59). Data derived from TCGA show that miR-106a is over-expressed in GC tissues in comparison to matching normal tissues.

miR-421. miR-421 (Figure 3B) is increased in GC and is associated with poor prognosis (60). An antagonist of 421 reduces TG of subcutaneously implanted SGC-790/1 cells in nude mice (60). E-Cadherin and caspase 3, key regulators in the process of epithelial mesenchymal transition (EMT) have been identified as targets of miR-421 (60-62). Data derived
miR-421. miR-421 is over-expressed in GC tissues in comparison to matching normal tissues. Data from TCGA show that miR-421 is over-expressed in GC tissues in comparison to matching normal tissues.

miR-589. miR-589 (Figure 3B) is up-regulated in GC tissues and associated with poor prognosis in patients with GC (63). miR-589 induces migration and invasion of GC cell lines MGC803 and BCG823 in vitro (63). Endogenous overexpression of miR-589 promotes lung metastasis of MGC-803 cells after tail vein injection (63). Leukemia inhibitory factor receptor (LIFR) was identified as a direct target of miR-589 (63). LIFR suppresses the in vitro effects of miR-589 as described above (63). It was shown that LIFR is essential for miR-589-mediated promotion of PI3K/AKT signaling activation (63). LIFR (CD118) is a low-affinity subunit of the LIFR and together with a high-affinity converter subunit binds leukemia inhibitory factor (LIF) with high affinity. LIF is an interleukin 6 (IL6) class cytokine (64). LIFR has been identified as a metastasis suppressor in hepatocellular carcinoma (65). Data derived from TCGA atlas confirm that miR-589 is over-expressed in GC tissues in comparison to corresponding normal tissues (Figure 2).

miRs Involved in Signaling Pathways

miR-19a. miR-19a (Figure 4) promotes proliferation and tumorigenicity of MGC-803 and SGC-7901 GC cells (66). In vivo, increased TG was noted with SGC-7901 cells overexpressing miR-19a after subcutaneous implantation (66). Suppressor of cytokine signaling-1 (SOCS-1) was identified as a direct target of miR-19a (66). miR-19a expression levels are inversely correlated with SOCS-1 levels in GC tissues (66). SOCS-1 is member of a family of eight proteins each of which contains a src homology 2 (SH2) domain and a COOH-terminal SOCS-box (67). SOCS-1 functions as an inhibitor of the janus tyrosine kinase (JAK) and signal transducer and activator of transcription 3 (STAT3) pathways (68, 69).

miR-19b, -20a, 92a. miRs-19b, -20a and 92a (Figure 4) are members of the mir-17-92 cluster and are overexpressed in human GC stem cells and are negatively correlated with the survival of GC patients (70). SGC7901 cells transduced with miRs-19b, -20a or -92a show improved TG after subcutaneous implantation into nude mice (70). Transcription factor E2F1 and homeobox-interacting protein kinase (HIPK) were identified as targets of the miRs of the miR-17-92 cluster which are involved in self-renewing of GC stem cells (70). E2F can activate transcription of β-catenin-interacting protein (ICAT), an inhibitor of β-catenin (71). HIPK1 phosphorylates homeodomain transcription factors and co-repressors of homeobox transcription factors and modulates β-catenin signaling by interaction with dishevelled, a multi-domain scaffold protein required for virtually all WNT signaling activities (72). Data derived from the TCGA show that miRs-19b, -20a and -92a are overexpressed in GC tissues in comparison to corresponding normal tissues (Figure 2).
miR-493. miR-493 (Figure 4) is up-regulated in GC and promotes proliferation of SGC-709 and MGC-803 GC cells (73). TG of MGC-803 GC cells overexpressing miR-493 is increased after subcutaneous implantation in comparison to the control cell line (73). Dickkopf-related protein-1 (DKK-1) has been identified as direct target of miR-493 (73). Ectopic expression of DKK-1 can rescue the effect of a miR-493 inhibitor on proliferation in vitro and TG in vivo (73). DKK-1 is an antagonist of the WNT/β-catenin signaling pathway by isolating the low-density lipoprotein receptor-related protein 6 (LRP6) co-receptor so that it can not aid in activating the WNT signaling pathway (74, 75). High DKK-1 expression regardless of β-catenin positivity is a crucial prognostic factor for predicting tumor recurrence and survival of patients with resected advanced GC (76). Data derived from TCGA show that miR-493 is over-expressed in GC tissues in comparison to corresponding normal tissues (Figure 2).

miR-664a-3p. miR-664a-3p (Figure 4) is up-regulated in GC tissues and promotes GC cell proliferation (77). miR-664a-3p mimics promote tumor volume of SGC790 and HGC27 GC tumor cells subcutaneously injected into nude mice, whereas a miR-664a-3p inhibitor decreases the tumor volume (77). MOB kinase activator 1A (MOB1A) was identified as a direct target of miR-664a-3p (77). MOB1A is a component of the Hippo pathway which is involved in restraining cell proliferation and promoting apoptosis. The Hippo pathway is frequently deregulated in different human cancers, but most Hippo pathway genes are not commonly mutated (78-80). MOB1A inhibits large tumor suppressor kinases 1 and 2 (LATS 1/2) which modulates two other kinases, nuclear dbf2-related 1 and 2 (NDR1 and NDR2) resulting in enrichment of yes-associated protein-1 (YAP) and transcriptional activator with PDZ-binding motif (TAZ) in the nucleus leading to a negative impact on transcription of Hippo pathway-related genes (78-80).

**micro-RNAs Modulating Apoptosis**

miRs-23a/b, -93. miRs-23a/b and -93 (Figure 4) are up-regulated in GC tissues in comparison to normal tissues (81, 82). Programmed cell death 4 (PDCD4) has been identified as a direct target of miRs-23a/b and -93 (81, 82). Introduction of miR-23a/b mimetics into MKN-45 and AGD GC cells reduces PDCD4 levels, whereas miR-23a/b antisense oligonucleotides increase PDCD4 levels (81). AGS cells transfected with PDCD4 small interfering RNA (siRNA) showed decreased apoptosis, transfection of a PDCD4 expression plasmid had the opposite effect (82).
**miR-135a.** miR-135a (Figure 4) is up-regulated in GC patients and is associated with poor prognosis (87). miR-135a correlates with resistance to oxaliplatin (OXA) (87). OXA-resistant GC cells proliferate in response to miR-135a expression (87). TG of MGC-803/OXA GC transfected with miR-135a was increased and TG was reduced with MGC-803/OXA cells transfected with a miR-13 functional inhibitor after subcutaneous implantation into nude mice (87). E2F1 and death-associated protein kinase 2 (DAPK2) were identified as direct targets of miR-135a, promoting OXA-resistance (87). DAPK2 is stimulated by E2F1 and induces apoptosis by the kruppel-like factor (KLF/Sp1) transcription factor pathway (88). Restoration of DAPK2 TS in cancer cells by fusion protein containing a tumor-targeting module and DAPK2 reconstitution is a therapeutic strategy to selectively induce apoptosis in cancer cells (89, 90). In patients with GC hypermethylation of the DAPK gene has been observed (91).

**miR-151-5p.** miR-151-5p (Figure 4) expression is increased by activated Notch1 pathway (92). miR-151 promotes growth of SC-M1 GC cells and induces focal adhesion kinase (FAK) (92). SC-M1 cells overexpressing miR-151-5p exhibit augmented tumor sizes in comparison to control cells after subcutaneous implantation into nude mice (92). After tail vein injection of these cells, metastatic nodules in the lungs were significantly increased (92). p53 was identified as a target of miR-151-5p (92). The apoptosis-mediating function of p53 in cancer is well documented (93,94). The suppressive effects of miR-151 antagonisms on Notch1 signalling-induced metastasis of SC-M1 cells could be partially recovered by cotransfection of an siRNA vector against p53 (92).

**microRNAs Interfering With the Cell-Cycle**

**miR-27a-3p.** miR-27a-3p (Figure 5A) is over-expressed in GC tissues and promotes proliferation and TC growth in NCI-N87,
MGC-803 and GES-1 GC cells (95). Ectopic expression of miR-27a-3p in GES-1 cells promotes tumor weight and volume after subcutaneous administration into immunodeficient mice, the opposite holds true for MGC-803 cells with inhibited expression of miR-27a-3p (95). B-cell translocation gene (BTG2) has been identified as a direct target of miR-27a-3p (95). BTG2 induces apoptosis and triggers cell cycle arrest by inhibiting G1/S transition (96, 97). BTG2 is frequently deleted or mutated in B-cell malignancies and functions as a TS in several types of tumors (98).

miR-340. miR-340 (Figure 5A) is up-regulated in GC tissues and cell lines (99). Elevated expression of miR-340 is correlated with adverse clinicopathological features and poor prognosis in GC patients (99). miR-340 promotes motility, proliferation and cell-cycle progression of GC cells such as SGC-7901 and MGC-803 (99). Inhibition of miR-340 decreased TG of MGC-803 cells in nude mice and cyclin G2 was identified as a direct target of miR-340 (99). CCNG2 is critical for the functional effects of miR-340 in GC cells, because knockdown of CCNG2 abrogated the effects of miR-340 knockdown in MGC-803 cells (99). CCNG2 is a regulator of cell proliferation and induces G1/S phase cell cycle arrest (100, 101). CCNG2 expression is decreased in GC (102). Based on data derived from TCGA, miR-240 is over-expressed in GC tissues in comparison to matching normal tissues (Figure 2).

**Other miRs Affecting Growth of Gastric Cancer**

**miR-10b.** miE-10b (Figure 5B) promotes proliferation, invasion, colony formation and EMT of HGC27 GC cells (103). MKN74 cells overexpressing miR-10b show increased tumor volume and weight and metastasis to the liver after subcutaneous implantation in nude mice (103). CUB and sushi multiple domains 1 (CSMD1) was identified as a target of miR-10b (103). Expression of CSMD1 was negatively correlated with expression of miR-10b in GC tissues (103). Inhibition of CSMD1 leads to activation of the NFĸB pathway resulting in up-regulation of cyclin D1 (CCND1) and EMT markers (103). CSMD1 is a single membrane spanning protein which contains 14 N-terminal CUB domains that are separated from each other by a SUSHI domain followed by an additional 15 tandem SUSHI domain segment and functions as a complement inhibitor (104). In melanoma cells, CSMD1 exhibits anti-tumor activity by inhibiting cell-cycle progression and apoptosis via the SMAD pathway (105). Loss of CSMD1 has been observed in head-and-neck squamous cell carcinoma, lung- and breast cancer (106).
**miR-130a.** miR-130a (Figure 5B) is elevated in GC cell lines (107). In BGC823 cells, miR-130a promotes proliferation and inhibits cell-cycle arrest in G1 phase, colony formation, cell invasion and migration as well as cell adhesion by targeting collapse response mediator protein 4 (CRMP4) (107). CRMP4 reversed the *in vitro* effects of miR-130a as described above (107). miR-130a functions as an oncomir. miR-130a accelerates TG of BGC823 cells in nude mice and depletion of CRMP4 with small hairpin RNA (shRNA) results in retardation of TG (107). CRMPs are a family of five cytosolic proteins which are expressed in the nervous system during development and through interactions with microtubules play important roles in axon formation and growth cone guidance and collapse (108). They are implicated in proliferation, apoptosis, differentiation, progression and metastasis of tumors (109). In melanoma cells, CRMP1 plays an anti-tumoral role in cell-cycle regulation and controlling apoptosis *via* the SMAD pathway (110). It was shown that VEGF promotes GC development by up-regulation of CRMP4 (111).

**miR-135b-5p.** miR-135b-5p (Figure 5B) expression in GC tissues is significantly higher compared to normal tissues (112). SGC-7901 GC cells infected with a lentivirus expressing a miR-135b-5p inhibitor exhibit reduced proliferation, suppressed cell-cycle progression and invasiveness and promotion of apoptosis (112). *In vivo*, this cell line has characteristics of reduced tumor growth in nude mice (112). Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family member 3 (CMTM3) was identified as a direct target of miR-135b-5p (112). CMTM3 is member of a family of nine genes in humans of the chemokine-like factor gene family similar to the chemokine and transmembrane 4 superfamilies of signaling molecules (113). It was previously shown that CMTM3 inhibits GC cell growth through apoptosis and its knockdown promotes metastasis of GC cells *via* the STAT3/Twist1/EMT signaling pathway (114-116). CMTM3 also decreases epidermal growth factor receptor (EGFR) expression and EGFR-mediated tumorigenicity in GC (117). Altogether, CMTM3 functions as a TS in GC and CMTMs exert TS functions in additional types of cancers (118).

**miR-448.** miR-448 (Figure 5B) is over-expressed in GC and is associated with poor survival (119). miR-448 promotes growth and carcinogenicity of MKN87 and SGC7901 GC cells *in vitro* and *in vivo* (119). Lysine (K)-specific demethylase 2B (KDM2B) was identified as a direct target of miR-448. Suppression of KDM2B promotes glycolysis in GC cells and miR-448 is a positive regulator of glycolysis (119). Inhibition of KDM2B induces expression of transcription factor MYC and glycolysis (119). KDM2B removes methyl groups from H3K36me2 and H3K4me3 of histones and inhibits glycolysis of cancer cells which are addicted to glycolysis in contrast to differentiated cells which use mitochondrial oxidative phosphorylation for energy production (119). MYC is known as inducer of glucose uptake and lactate production in cancer cells (120). However, from a general point of view, one should keep in mind that KDM2B is a double-edged sword in the regulation of cancer development which can act in a context-dependent manner as a TS or as an oncogene (121).

**miR-487a.** miR-487a (Figure 5B) promotes proliferation and suppresses apoptosis of GC *in vitro* and knockdown of miR-487a has opposite effects (122). miR-487a enhances growth of GC xenografts (122). T cell intracellular antigen-1 (TIA-1) has been identified as a direct target of miR-487a (122). TIA-1 contains three RNA recognition domains, the latter two have been shown to be important for RNA binding and selectivity (123). TIA-1 alters both co-transcriptional and post-transcriptional RNA processing and binds to VEGF-A mRNA (124). Alternative splicing of VEGF induced by TIA-1 influences the angiogenic capability of colorectal cancer (125). TIA-1 also acts as a stress-induced translational inhibitor localizing to stress granules containing polyA RNA (126). Alternative splicing, export and translational regulation have been shown to contribute to tumor formation and progression and these events are attractive targets for therapeutic intervention (127, 128).

**Technical Aspects**

Oncomirs can be inhibited at several stages of their generation: at the level of transcription by RNA Pol II or III, at the level of precursor cleavage by DICER and at the level of functional inhibition of mature RNA, resulting in mRNA degradation and functional repression (129). The latter is the most popular mode of intervention. miRs inhibit several mRNAs, wheras siRNA inhibits only one specific mRNA (130). siRNAs are 21-23 nt RNA duplexes with two nts 3’-overhang fully complementary to mRNA, whereas miRs are 19-25 nts RNA duplexes with two nts 3’-overhang with complementary binding in the seed region (nts 2 to 7 at the 5’-end) of the corresponding miR to the 3’-UTR of the mRNA (130). siRNA mediates endonucleolytic cleavage of the corresponding mRNA, wheras miRs preferentially induce degradation of mRNAs and translational repression (129, 130).

Anti-miR-oligonucleotides (AMO) are designed to bind a sequence complimentary to mature miRs. Incorporation of a phosphoro-thioate backbone and ribose 2’-OH modification (2’-F, 2’-O-methyl, 2’-O-methoxyethyl) have improved binding and pharmaco-kinetic and pharmako-dynamic properties of AMO’s (130). Anti-miRs with a 2’-O-methoxyethyl modification are referred to as antagonirs. Also, incorporation of locked nucleic acids (LNA) which...
contain an additional bridge between the 2’-oxygen and the 4’-carbon of the pentose have significantly improved the drug-like properties of AMO’s (131).

Peptide nucleic acids (PNA) are under evaluation as miR-inhibitory agents (132). In these agents the deoxy-phosphate backbone of nucleic acids is replaced by a polyamide chain of N-aminoethyl-glycyl units to result in polymers with an artificial backbone structure as a main chain with similarity to DNA or RNA (132). PNAs are resistant to nucleases, have stronger affinity and greater specificity for DNA and RNA than natural nucleic acids (132).

Identification of small molecule inhibitors of miRs is under active investigation. Several inhibitors which inhibit transcription of defined miRs have been identified, however specificity issues and target deconvolution of the identified compounds have to be tackled (133). Identification of compounds which target secondary elements in human miR hairpin precursors have been reported (134). It has been shown that a secondary structure of pre-miRs contains a narrow groove to which a positively charged compound can bind at nM affinity, making it a druggable candidate (135). Combination of bioinformatics and high throughput screening has revealed compounds which inhibit DICER cleavage sites in pre-miRs (136).

miR sponges are DNA constructs which contain artificially designed, tandemly reiterated miR-binding sites thus competing for miRs with the mRNA under consideration (137). They have to be transduced into the corresponding recipient cells (137). Furthermore, oncomirs have been knocked-out by making use of the genome-editing tool clustered regularly interspaced short palindromic repeats-CRISPR associated (CRISPR-CAS) (138, 139).

However, many additional issues have to be optimized case-by-case for optimization of therapeutic efficacy of miR-inhibitors. Extended circulation time by PEGylation [attachment of polyethylene glycol (PEG)] polymer chains attached to miRs has been achieved (140). Optimization of delivery is a crucial process for achieving therapeutic efficacy. Cationic complexes which interact with negatively charged RNA through electrostatic interactions have been created with synthetic polyethyleneimine (PEI) as early generation polymers for RNA delivery (141). Also, dendrimers, branched synthetic polymers are under evaluation as delivery agents (142, 143). Polymers also promote endosomal escape of miRs thus avoiding endosomal-lysosomal RNA degradation. Poly (lactic-co-glycolic acid) (PLGA) is an FDA-approved synthetic biodegradable polymer for delivery of miR-inhibitors (144). Moreover, the use of cyclodextrins as delivery agents has been explored (145). Another class of delivery agents are lipid-based agents. These agents are composed of cationic lipids and liposomes which can form complexes with RNA through electrostatic interactions (146). Also, lipopolyplexes composed of polymers and lipids are under investigation as delivery agents (147). Conjugation of miRs to specific ligands such as N-acetylglactosamine, a triantennary N-acetylglactosamine, high-affinity ligand specific for the asialoglycoprotein receptor, enhances potency of anti-sense oligonucleotides 6-10-fold in mouse liver (148). Several critical issues are not discussed in further details in this review such as toxicity issues, cytokine release syndrome, delivery into target tissues, efficient release of miR-related agents from endosomes, optimization of pharmaco-kinetic and pharmaco-dynamic properties, excretion by the kidneys and unspecific hybridization (149-155).

**Synopsis.** We have identified 31 miRs covering 26 different targets which promote growth of GC cells *in vitro* and *in vivo* as xenografts. Five miRs (miRs -10b, 151-5p, -187, 532-3p and -589) additionally have an impact on metastasis. Thirteen of the identified miRs (-19b, -20s, -25, -92a, -106a, -135a, -187, -221-3p, -340a, -421, -493, -575 and -589) correlate with worse prognosis in GC patients. The oncomirs identified are up-regulated in GC tissues, the corresponding targets are down-regulated. The homogeneity of expression of the target candidates miRs should be investigated in more details. As outlined previously GC patients have a high relapse rate after surgical resection and following chemotherapy. It would be of interest to investigate, whether inhibition of any of the identified miRs has an impact on established metastases in preclinical *in vivo* models.

**miRs Landscape Cancer**

miR-related therapeutics may be particulary suited for complex, multigenic disorders such as cancer, since they can interfere with several pathways. The first micro-RNA based therapeutic evaluated in clinical studies in cancer patients was MRX-34 by Mirna Therapeutics (156, 157). MRX-34 is an intra-venously injected liposomal formulation of a miR-34 mimetic. miR-34 acts as a TS and inhibits proliferation, invasion by inhibition of WNT, NOTCH, TGFβ and EMT-related transcription factors (156,157). Repression of miR-34 target genes such as forkhead box protein P1 (FOXP1), B-cell lymphoma 2 (BCL2), histone deacetylase 1 (HDAC1) and cyclin B1 (CTNNB1) was demonstrated in cancer patients, however, clinical studies were halted due to multiple immune-related side effects (156, 157). Another agent is a miR-16-based mimetic which is administered as EGFR-conjugated bacterial mini-cells (158). The agent was intra-venously injected into recurrent patients with malignant pleural mesothelioma with signs of radiologic progression after chemotherapy (NCI02369198). Twenty-two patients were enrolled and one objective response (5%), in 15 patients (68%) stabilisation of disease and in 6 patients (27%) progression of disease was observed with an
acceptable safety profile (158). miR-16 preferentially targets BCL2 (159). Inhibition of miR-155 is pursued by miRagen. miR-155 acts oncoprogenically in many haematological diseases and its expression correlates with prognosis in lymphoma and leukemic diseases (160). Cobomersen is a 14 nucleotides mixed-type (deoxynucleotide plus LNA phosphorothioate-based oligonucleotide which inhibits proliferation of tumor cells and T-cell activation and simultaneously regulates JAK/STAT, MAPK/ERK and PI3K/AKT signalling (160). In 68 patients with cutaneous T-cell lymphoma (CTCL), acute T-cell leukemia/lymphoma (ATLL), diffuse B-cell lymphoma (DBCL) and chronic lymphoproliferative leukemia (CLL) cobomersen was administered for 2 years, reversal of the disease genetic signature and no serious side effects were observed (www.miragen.com). In CTLL patients cobomersen has reduced lesion severity after i.v. injection in a Phase I study. It remains to be seen whether miR-based therapeutic agents have a bright future in the space of cancer therapy.

Conflicts of Interest

AN and FB are employees of Roche; UHW was an employee of Roche.

Authors’ Contributions

AN and UHW: design and writing of the paper; FB: bio-informatic analysis.

References

1 Van Cutsem E, Sagaert X, Topal B, Haustermans K and Prenen H: Gastric cancer. Lancet 388: 2654-2664, 2016. PMID: 27156933. DOI: 10.1016/S0140-6736(16)30354-3

2 Hu B, El Hajj N, Sittler S, Lammert N, Barnes R and Meloni-Ehrg A: Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol 3: 251-261, 2012. PMID: 22943016. DOI: 10.3978/j.issn.2078-6891.2012.021

3 Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, Ajani JA and Lee JS: Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res 23: 4441-4449, 2017. PMID: 28747339. DOI: 10.1158/1078-0432.CCR-16-2211

4 Venerito M, Link A, Rokkas T and Malfetathirner P: Review: Gastric cancer-clinical aspects. Helicobacter 24(Suppl 1): e12643, 2019. PMID: 31486238. DOI: 10.1111/hel.12643

5 Ortidura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciaridello F and De Vita F: Treatment of gastric cancer. World J Gastroenterol 20: 1635-1649, 2014. PMID: 24587643. DOI: 10.3748/wjg.v20.i7.1635

6 Bonelli P, Borrelli A, Tuccillo FM, Silvestro L, Palaia R, Buonaguro FM: Precision medicine in gastric cancer. World J Gastrointest Oncol 11: 804-829, 2019. PMID: 31662821. DOI: 10.4251/wjgo.v11.i10.804

7 Figueroa-Protti L, Soto-Molinari R, Calderón-Osorno M, Mora J and Alpizar-Alpizar W: Gastric cancer in the era of immune checkpoint blockade. J Oncol 2019: 1079710, 2019. PMID: 31662748. DOI: 10.1155/2019/1079710

8 Kwak Y, Seo AN, Lee HE and Lee HS: Tumor immune response and immunotherapy in gastric cancer. J Pathol Transl Med 54(1): 20-33, 2020. PMID: 31674166. DOI: 10.4132/jptm.2019.10.09

9 Akin T, Bregni G, Camera S, Deleporte A, Hendlisz A and Scalfani F: PD-1 and PD-L1 inhibitors in oesophageo-gastric cancers. Cancer Lett 469: 142-150, 2020. PMID: 31669518. DOI: 10.1016/j.canlet.2019.10.036

10 Hironaka S: Anti-angiogenic therapies for gastric cancer. Asia Pac J Clin Oncol 15: 208-217, 2019. PMID: 31111678. DOI: 10.1111/ajco.13174

11 Bartel DP: Metazoan microRNAs. Cell 173: 20-51, 2018. PMID: 29570994. DOI: 10.1016/j.cell.2018.03.006

12 Slotwinski R, Lech G and Slotwinska SM: microRNA in pancreatic diagnosis and therapy. Cent Eur J Immunol 43: 314-324, 2018. PMID: 30588176. DOI: 10.5114/cej.2018.80051

13 Li Z and Rana TM: Therapeutic targeting of microRNAs. Current status and future challenges. Nat Rev Drug Discov 13: 622-638, 2014. PMID: 25011539. DOI: 10.1038/nrd4339

14 Rupaimoole R and Slack FJ: MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16: 203-222, 2017. PMID: 28209991. DOI: 10.1038/nrd.2016.246

15 Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol 9: 287-314, 2014. PMID: 24078933. DOI: 10.1146/annurev-pathol-012513-104715

16 Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S, Valtieri M, Calin GA, Liu CG, Sorrentino A, Croce CM and Peschle C: MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 102: 18081-18086, 2005. PMID: 16330772. DOI: 10.1073/pnas.0506216102

17 Garofalo M, Quintavalle C, Romano G, Croce CM and Condorelli G: miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 12: 27-33, 2012. PMID: 22082479. DOI: 10.2174/156652412793871670

18 Pekarsky Y and Croce CM: Role of miR-15/16 in CLL. Cell Death Differ 22: 6-11, 2015. PMID: 24971479. DOI: 10.1038/cdd.2014.87

19 Callegari E, Elamin BK, Giannone F, Iacovelli R, D’Abundo L, Ferracin M, Bassi C, Zagatti B, Corrà F, Miotti E, Lupini L, Bolondi L, Gramantieri L, Croce CM, Sabbioni S and Negrini M: Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 59: 1025-1033, 2019. PMID: 31674166. DOI: 10.1002/hep.25747

20 Weidle UH, Dickopf S, Hintermair C, Kollmorgen G and Brinkmann U: The role of microRNAs in breast cancer: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16: 224-234, 2017. PMID: 28209991. DOI: 10.1038/nrd.2016.246

21 Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol 9: 287-314, 2014. PMID: 24078933. DOI: 10.1146/annurev-pathol-012513-104715

22 Weidle UH, Hong J, Alpizar Alpizar W, Blachar D, Bregni G, Camera S, Deleporte A, Hendlisz A and Scalfani F: PD-1 and PD-L1 inhibitors in oesophageo-gastric cancers. Cancer Lett 469: 142-150, 2020. PMID: 31669518. DOI: 10.1016/j.canlet.2019.10.036

23 Weidle UH, Epp A, Birzele F and Brinkmann U: The functional role of prostate cancer metastasis-related microRNAs. Cancer Genomics & Proteomics 18: 1-15 (2021). DOI: 10.21873/cgp.20062
Weidle et al: microRNAs With Efficacy in Gastric Cancer-related Preclinical In Vivo Models (Review)

Proteomics 16: 1-19, 2019. PMID: 30587496. DOI: 10.21873/cgp.20108

23 Weidle UH, Birzele F and Nopora A: MicroRNAs as potential targets for therapeutic intervention with metastasis of non-small cell lung cancer. Cancer Genomics Proteomics 16: 99-119, 2019. PMID: 30850362. DOI: 10.21873/cgp.20116

24 Weidle UH, Birzele F and Nopora A: Pancreatic Ductal Adenocarcinoma: MicroRNAs affecting tumor growth and metastasis in preclinical in vivo models. Cancer Genomics Proteomics 16: 451-464, 2019. PMID: 31659100. DOI: 10.21873/cgp.20149

25 Shi J, Zhang Y, Jin N, Li Y, Wu S and Xu L: MicroRNA-221-23p plays an oncogenic role in gastric carcinoma by inhibiting PTEN expression. Oncol Rep 25: 523-536, 2017. PMID: 27712596. DOI: 10.3727/096560416X1475628219385

26 Seok JK, Lee SH, Kim MJ and Lee YM: MicroRNA-382 induced by HIF-1α is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog. Nucleic Acids Res 42: 8062-8072, 2014. PMID: 24914051. DOI: 10.1093/nar/gku1215

27 Ma J, Liu J, Wang Z, Gu X, Fan Y, Zhang W, Xu L, Zhang J and Cai D: NF-kappaB-dependent microRNA-425 upregulation promotes gastric cancer cell growth by targeting PTEN upon IL-1β induction. Mol Cancer 13: 40, 2014. PMID: 24571667. DOI: 10.1186/1476-4598-13-40

28 Wang YN, Xu F, Zhang P, Wang P, Wei YN, Wu C and Cheng SJ: MicroRNA-575 regulates development of gastric cancer by targeting PTEN. Biomed Pharmacother 93: 108716, 2019. PMID: 30844657. DOI: 10.1016/j.biopha.2019.108716

29 Papa A and Pandolfi PP: The PTEN-PI3K axis in cancer. Biomolecules 9(4): 153, 2019. PMID: 30999672. DOI: 10.3390/biom9040153

30 Lee YR, Chen M and Pandolfi PP: The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol 19: 547-562, 2018. PMID: 29586004. DOI: 10.1038/s41591-018-0015-0

31 He C, Wang L, Zhang J and Xu H: Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RUNX3 in gastric cancer. FEBS Lett 588: 4504-4512, 2014. PMID: 25448600. DOI: 10.1016/j.febslet.2014.09.047

32 Cheng LRA, Wu S and Zhang Y: ZHX1 inhibits gastric cancer cell growth through inducing cell-cycle arrest and apoptosis. J Cancer 7: 60-68, 2016. PMID: 26722361. DOI: 10.7150/jca.12973

33 Zhu Y, Ma D and Ji C: Zinc fingers and homeobox families in human diseases. Cancer Gene Ther 22: 223-226, 2015. PMID: 25857360. DOI: 10.1038/cgt.2015.2

34 Li N, Zhang QY, Zou JL, Li ZW, Wei YN, Ge S, Zhu Y, Gao J and Shen L: miR-215 promotes malignant progression of gastric cancer by targeting RUNX1. Oncotarget 7: 4817-4828, 2016. PMID: 26716895. DOI: 10.18632/oncotarget.6736

35 Ma X, Huang M, Wang Z, Liu B, Zhu Z and Li C: ZHX1 inhibits gastric cancer cell growth through inducible cell-cycle arrest and apoptosis. J Cancer 7: 60-68, 2016. PMID: 26722361. DOI: 10.7150/jca.12973
Welcker M and Clurman BE: FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8: 83-93, 2008. PMID: 18094723. DOI: 10.1038/nrc2290

Cheng Y and Li G: Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev 31: 75-87, 2012. PMID: 22124735. DOI: 10.1007/s10555-011-9330-z

Cao J, Ge MH and Ling ZQ: Fbxw7 tumor suppressor: A vital regulator contributes to human tumorigenesis. Medicine (Baltimore) 95: e2496, 2016. PMID: 26886596. DOI: 10.1097/MD.0000000000002496

Yang G, Gong Y, Wang Q, Wang L and Zhang X1: miR-100 antagonist triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation. Oncogene 36: 1023-1037, 2017. PMID: 27524417. DOI: 10.1038/onc.2016.270

Benard G, Neutzner A, Peng G, Wang C, Livak F, Youle RJ and Karbowski M: IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax and apoptosis activation. EMBO J 29: 1458-1471, 2010. PMID: 20300062. DOI: 10.1038/embj.2010.39

Ho SR, Mahanic CS, Lee YJ and Lin WC: RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis during DNA damage. Proc Natl Acad Sci USA 111: E2646-2655, 2014. PMID: 24979766. DOI: 10.1037/pnas

Huang J, Xu LG, Liu T, Zhai Z and Shu HB: The p53-inducible E3 ubiquitin ligase p53RFP induces p53-dependent apoptosis. FEBS Lett 580: 940-947, 2006. PMID: 16427630. DOI: 10.1016/j.felslet.2005.09.105

Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J and Xu N: miR-106a is frequently upregulated in gastric cancer and inhibits the extrinsic pathway by targeting FAS. Mol Carcinog 52: 634-646, 2013. PMID: 22431000. DOI: 10.1002/mca.21899

Zhu M, Zhang N, He S, Yan R and Zhang J: MicroRNA-106a functions as an oncogene in human gastric cancer and contributes to proliferation and metastasis in vitro and in vivo. Clin Exp Metastasis 33: 509-519, 2016. PMID: 27142596. DOI: 10.1007/s10555-016-9759-9

Igney FH and Kramper PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288, 2002. PMID: 12001989. DOI: 10.1038/nrc7776

Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A and Ceppi P: The role of CD95 and CD95 ligand in cancer. Cell Death Differ 22: 885-886, 2015. PMID: 25849030. DOI: 10.1038/cdd.2015.25

Ge X, Liu X, Lin F, Li P, Liu K, Geng R, Dai C, Lin Y, Tang W, Wu Z, Chang J, Lu J and Li J: MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget 7: 24466-24482, 2016. PMID: 27016414. DOI: 10.18632/oncotarget.8228

Yu W, Yang L, Li T and Zhang Y: Cadherin signaling in cancer: Its functions and role as a therapeutic target. Front Oncol 9: 989, 2019. PMID: 31637214. DOI: 10.3389/fonc.2019.00989

Gloushankova NA, Zhitinyyk IV and Rubtsova SN: Role of epithelial-mesenchymal transition in tumor progression. Biochemistry (Mosc) 83: 1469-1476, 2018. PMID: 30878022. DOI: 10.1134/S0006297918120052
functions as an oncogene by targeting Hippo pathway in the development of gastric cancer. Cell Prolif 52: e12567, 2019. PMID: 30883979. DOI: 10.1111/cpi.12567.

Harvey KF, Zhang X and Thomas DM: The Hippo pathway and human cancer. Nat Rev Cancer 13: 246-257, 2013. PMID: 23467301. DOI: 10.1038/nrc3458.

Meng Z, Moroishi T and Guan KL: Mechanisms of hippo pathway regulation. Genes Dev 30: 1-17, 2016. PMID: 26728553. DOI: 10.1101/gad.274027.

Moon S, Yeon Park S and Woo Park H: Regulation of the Hippo pathway in cancer biology. Cell Mol Life Sci 75: 2303-2319, 2018. PMID: 29602952. DOI: 10.1007/s00018-018-2804-1.

Hu X, Wang Y, Liang H, Fan Q, Zhu R, Cui J, Zhang W, Zen K, Zhang CY, Hou D, Zhou Z and Chen X: miR-23a/b promote tumor growth and suppress apoptosis by targeting PDCD4 in gastric cancer. Cell Death Dis 8: e3059, 2017. PMID: 28981115. DOI: 10.1038/cddis.2017.

Liang H, Wang F, Chu D, Zhang W, Liao Z, Fu Z, Yan X, Zhu H, Guo W, Zhang Y, Guan W and Chen X: miR-93 functions as an oncomiR for the downregulation of PDCD4 in gastric carcinoma. Sci Rep 6: 23772, 2016. PMID: 27021515. DOI: 10.1038/rep23772.

Wang W, Zhao J, Wang H, Sun Y, Peng Z, Zhou G, Fan L, Wang X, Yang S, Wang R and Fang D: Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression. Exp Cell Res 316: 2456-2464, 2010. PMID: 20595055. DOI: 10.1016/j.yexcr.2010.05.027.

Matsushashi S, Manirajjaman M, Hamajima H and Ozaki I: Control mechanisms of the tumor suppressor PDCD4: Expression and functions. Int J Mol Sci 20, 2019. PMID: 31075975. DOI: 10.3390/ijms20092304.

Ma G, Zhang H, Dong M, Zheng X, Ozaki I, Matsushashi S and Guo K: Downregulation of programmed cell death 4 (PDCD4) in tumorigenesis and progression of human digestive tract cancers. Tumour Biol 34: 3879-3885, 2013. PMID: 23838800. DOI: 10.1007/s13277-013-0975-9.

Guo PT, Yang D, Sun Z and Xu HM: PDCD4 functions as a suppressor for pT2a and pT2b stage gastric cancer. Oncol Rep 29: 1007-1012, 2013. PMID: 23314309. DOI: 10.3892/or.2013.2232.

Yan LH, Chen ZN, Li-Li, Chen J, Wei WE, Mo XW, Qin YZ, Lin Y and Chen JS: miR-135a promotes gastric cancer progression and resistance to oxaliplatin. Oncotarget 7: 70699-70714, 2016. PMID: 27683111. DOI: 10.18632/oncotarget.12208.

Britschgi A, Trinh E, Rizzi M, Jenal M, Res A, Tobler A, Fey MF, Helin K and Tschan MP: DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function. Oncogene 27: 5706-5716, 2008. PMID: 18521079. DOI: 10.1038/onc.2008.179.

Tur MK, Daramola AK, Gattenlöcher S, Herling M, Chetty S and Barth S: Restoration of DAP kinase tumor suppressor function: A therapeutic strategy to selectively induce apoptosis in cancer cells using immunokinase fusion proteins. Biomedicines 5: pii: E59, 2017. PMID: 28976934. DOI: 10.3390/biomedicines5040059.

Huang Y, Chen L, Guo L, Hupp TR and Lin Y: Evaluating DAPK as a therapeutic target. Apoptosis 19: 371-386, 2014. PMID: 24305735. DOI: 10.1007/s10495-013-0919-2.

Chan AW, Chan MW, Lee TL, Ng EK, Leung WK, Lau JY, Tong JH, Chan PK and To KF: Promoter hypermethylation of death-associated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep 13: 937-941, 2005. PMID: 15809761.
106 Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD and Brose MS. Characterization of CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther 8: 907-916, 2009. PMID: 19276661. DOI: 10.4161/cbt.8.10.8132

107 Zhou Y, Li R, Yu H, Wang R and Shen Z: microRNA-130a is an oncomir suppressing the expression of CRMP4 in gastric cancer. Oncotarget 7: 3893-3905, 2017. PMID: 28831264. DOI: 10.2147/OTC.S139443

108 Arimura N, Menager C, Fukata Y and Kaibuchi K: Role of CRMP-2 in neuronal polarity. J Neurobiol 58: 34-47, 2004. PMID: 14598368. DOI: 10.1002/neu.10269

109 Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD and Brose MS. Characterization of CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther 8: 907-916, 2009. PMID: 19276661. DOI: 10.4161/cbt.8.10.8132

110 Su Y, Lin Y, Zhang L, Liu B, Yuan W, Mo X, Yang S, Ding S and Han W: CMTM3 decreases EGFR expression and EGFR-mediated tumorigenicity by promoting Rab8 activity in gastric cancer. Cancer 386: 77-86, 2016. PMID: 27867015. DOI: 10.1016/j.canlet.2016.11.015

111 Chen S, Zhang X, Peng J, Zhai E, He Y, Wu H, Chen C, Ma J, Tan F, Thiele CJ and Li Z: Collapsin response mediator proteins: an oncomir suppressing the expression of CRMP4 in gastric cancer. Oncotarget 7: 3893-3905, 2017. PMID: 28831264. DOI: 10.2147/OTC.S139443

112 Zhou Y, Li R, Yu H, Wang R and Shen Z: microRNA-130a is an oncomir suppressing the expression of CRMP4 in gastric cancer. Oncotarget 7: 3893-3905, 2017. PMID: 28831264. DOI: 10.2147/OTC.S139443

113 Arimura N, Menager C, Fukata Y and Kaibuchi K: Role of CRMP-2 in neuronal polarity. J Neurobiol 58: 34-47, 2004. PMID: 14598368. DOI: 10.1002/neu.10269

114 Lu J, Wu QQ, Zhou YB, Zhang KH, Pang BX, Li L, Sun N, Wang HS, Zhang S, Li WJ, Zheng W and Liu W: Cancer research advance in CKLF-like MARVEL transmembrane domain containing member family (Review). Asian Pac J Cancer Prev 17: 2741-2744, 2016. PMID: 27356683.

115 Hong X, Xu Y, Qiu X, Zhu Y, Feng X, Ding Z, Zhang S, Zhong L, Zhan Y, Yu C, Hong X and Cai J: MiR-448 promotes glycolytic metabolism of gastric cancer by downregulating KDM2B. Oncotarget 7: 22092-22102, 2016. PMID: 26999077. DOI: 10.18632/oncotarget.8020

116 Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD and Brose MS. Characterization of CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther 8: 907-916, 2009. PMID: 19276661. DOI: 10.4161/cbt.8.10.8132

117 Zhou Y, Li R, Yu H, Wang R and Shen Z: microRNA-130a is an oncomir suppressing the expression of CRMP4 in gastric cancer. Oncotarget 7: 3893-3905, 2017. PMID: 28831264. DOI: 10.2147/OTC.S139443

118 Lu J, Wu QQ, Zhou YB, Zhang KH, Pang BX, Li L, Sun N, Wang HS, Zhang S, Li WJ, Zheng W and Liu W: Cancer research advance in CKLF-like MARVEL transmembrane domain containing member family (Review). Asian Pac J Cancer Prev 17: 2741-2744, 2016. PMID: 27356683.

119 Hong X, Xu Y, Qiu X, Zhu Y, Feng X, Ding Z, Zhang S, Zhong L, Zhan Y, Yu C, Hong X and Cai J: MiR-448 promotes glycolytic metabolism of gastric cancer by downregulating KDM2B. Oncotarget 7: 22092-22102, 2016. PMID: 26999077. DOI: 10.18632/oncotarget.8020

120 Wahlström T and Henriksson MA: Impact of MYC in regulation of tumor cell metabolism. Biochim Biophys Acta 1849: 563-569, 2015. PMID: 25038584. DOI: 10.1016/j.bbadis.2014.07.004

121 Yan M, Yang X, Wang H and Shao Q: The critical role of histone lysine demethylase KDM2B in cancer. Am J Transl Res 10: 2222-2233, 2018. PMID: 30210666.

122 Yang X, Wang M, Lin B, Yao D, Li J, Tang X, Li S, Liu Y, Xie R, Yu S: miR-487a promotes progression of gastric cancer by targeting TIA1. Biochimie 154: 119-126, 2018. PMID: 30414499. DOI: 10.1016/j.biochi.2018.06.006

123 Bauer WJ, Heath J, Jenkins JL and Kielkopf CL: Three RNA recognition motifs participate in RNA recognition and structural organization by the pro-apoptotic factor TIA-1. J Mol Biol 415: 727-740, 2012. PMID: 22154808. DOI: 10.1016/j.jmb.2011.11.040

124 Suswam EA, Li YY, Mahtani H and King PH: Novel DNA-binding properties of the RNA-binding protein TIAR. Nucleic Acids Res 43: 4507-4518, 2015. PMID: 16091628. DOI: 10.1093/nar/gki763

125 Ferrara N, Houck KA, Jakeman LB, Winer J and Leung DW: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47: 211-218, 1991. PMID: 1791185. DOI: 10.1002/jcb.20470305

126 Izquierdo JM and Valcárcel J: Two isoforms of the T-cell protein complex CRMP4. Oncotarget 7: 17074-17086, 2016. PMID: 26934544. DOI: 10.18632/oncotarget.7717

127 Venables JP: Unbalanced alternative splicing and its significance in cancer. Bioessays 28: 378-386, 2006. PMID: 16547952. DOI: 10.1010/ies.bies.20390

128 Eberhardt W, Doller A, Akool el-S and Pfeilschifter J: Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther 114: 56-73, 2007. PMID: 17320967. DOI: 10.1016/j.pharmthera.2007.01.002

129 Lam JK, Chow MY, Zhang Y, Leung SW: siRNA versus miRNA agents by inhibition of oncogenic microRNAs. Int J Mol Sci 19: pii: E65, 2017. PMID: 29280958. DOI: 10.3390/ijms19010065

130 Nguyen DD and Chang S.: Development of novel therapeutic agents by inhibition of oncogenic microRNAs. Int J Mol Sci 19: pii: E65, 2017. PMID: 29280958. DOI: 10.3390/ijms19010065

131 Vester B and Wengel J: LNA (Locked Nucleic Acid): High-performance oligonucleotides for microRNA inhibition in the absence of a transfection reagent. Oligonucleotides 25: 225-230, 2010. PMID: 20946011. DOI: 10.1089/oli.2010.0238
133 Di Giorgio A, Tran TPA 1 and Duca M: Small-molecule approaches toward the targeting of oncogenic miRNAs: Roadmap for the discovery of RNA modulators. Future Med Chem 8: 803-816, 2016. PMID: 27149207. DOI: 10.4155/fmc-2016-0018

134 Biao Liu B, Childs-Disney JL, Znosko BM, Wang D, Fallahi M, Gallo SM and Disney MD: Analysis of secondary structural elements in human microRNA hairpin precursors. BMC Bioinformatics 17: 112, 2016. PMID: 26928172. DOI: 10.1186/s12859-016-0960-6

135 Thomas JR and Hergenröther PJ: Targeting RNA with small molecules. Chem Rev 108: 1171-1224, 2008. PMID: 18361529. DOI: 10.1021/cr0701546

136 Haga CL, Velagapudi SP, Childs-Disney J, Strivelli J, Disney MD and Phinney DG: Rapid generation of miRNA inhibitor leads by bioinformatics and efficient high-throughput screening methods. Methods Mol Biol 1517: 179-198, 2017. PMID: 27924483. DOI: 10.1007/978-1-4939-6563-2_13

137 Chen L, Zhang K, Shi Z, Zhang A, Jia Z, Wang G, Pu P, Kang C and Lei L: A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo. Oncol Rep 31: 1573-1580, 2014. PMID: 24503899. DOI: 10.3892/or.2014.3012

138 Mali P, Esvelt KM and Church GM: Cas9 as a versatile tool for engineering biology. Nat Methods 10: 957-963, 2013. PMID: 24076990. DOI: 10.1038/nmeth.2649

139 Chang H, Yi B, Ma R, Zhang X, Zhao H and Xi Y: CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. Sci Rep 6: 22312, 2016. PMID: 26924382. DOI: 10.1038/srep22312

140 Nosova AS, Koloskova OO, Nikonova AA, Simonova VA, Smirnov VV, Kudlay D and Khaibou MR: Diversity of PEGylation methods of liposomes and their influence on RNA delivery. Medchemcomm 10: 369-377, 2019. PMID: 3105904. DOI: 10.1039/c8md00515j

141 Neuberg P and Kichler A: Recent developments in nucleic acid nanocarriers for cancer therapy. Adv Drug Deliv Rev 116, 2014. PMID: 25011539. DOI: 10.1016/j.addr.2013.12.008

142 Rago M, Fattovich G, plugs D, Hebrok M, Stosiek P, Zinaj S, Haskova S, Mihalik P, Kozarova P, Dejnarova M et al: miRNA-429 as a prognostic factor in patients with primary hepatic colorectal cancer. Oncol Rep 38: 1373-1379, 2017. PMID: 28420910. DOI: 10.3892/or.2016.4582

143 Di Giorgio A, Tran TPA 1 and Duca M: Small-molecule approaches toward the targeting of oncogenic miRNAs: Roadmap for the discovery of RNA modulators. Future Med Chem 8: 803-816, 2016. PMID: 27149207. DOI: 10.4155/fmc-2016-0018

144 Videira M, Arranja A, Rafael D and Gaspar R: Preclinical development of siRNAs for siRNA therapeutics. Nat Mater 13: 622-638, 2014. PMID: 25011539. DOI: 10.1038/nmd4359

145 Garofalo M, Leva GD and Croce CM: MicroRNAs as anti-cancer therapy, Curr Pharm Des 20: 5328-5335, 2014. PMID: 24479801. DOI: 10.2174/1381612820666140128211346

146 Biao Liu B, Childs-Disney JL, Znosko BM, Wang D, Fallahi M, Gallo SM and Disney MD: Analysis of secondary structural elements in human microRNA hairpin precursors. BMC Bioinformatics 17: 112, 2016. PMID: 26928172. DOI: 10.1186/s12859-016-0960-6

147 Chang H, Yi B, Ma R, Zhang X, Zhao H and Xi Y: CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. Sci Rep 6: 22312, 2016. PMID: 26924382. DOI: 10.1038/srep22312

148 Nosova AS, Koloskova OO, Nikonova AA, Simonova VA, Smirnov VV, Kudlay D and Khaibou MR: Diversity of PEGylation methods of liposomes and their influence on RNA delivery. Medchemcomm 10: 369-377, 2019. PMID: 3105904. DOI: 10.1039/c8md00515j

149 MacLeod AR and Crooke ST: RNA therapeutics in oncology: Advances, challenges, and future directions. J Clin Pharmacol 57(Suppl 10): S43-S59, 2017. PMID: 21525952. DOI: 10.1038/gt.2011.50

150 Li Z and Rana TM: Therapeutic targeting of microRNAs: Current status and future challenges. Nat Rev Drug Discov 13: 622-638, 2014. PMID: 25011539. DOI: 10.1038/nmd4359

151 Garofalo M, Leva GD and Croce CM: MicroRNAs as anti-cancer therapy, Curr Pharm Des 20: 5328-5335, 2014. PMID: 24479801. DOI: 10.2174/1381612820666140128211346

152 Malek A, Merkel O, Fink L, Czubayko F, Kissel T and Aigner A: In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI-(PEG)/siRNA complexes. Toxicol Appl Pharmacol 236: 97-108, 2009. PMID: 19371615. DOI: 10.1016/j.taap.2009.01.014

153 Wang AZ, Langer R and Farokhzad OC: Nanoparticle delivery of cancer drugs. Annu Rev Med 63: 185-198, 2012. PMID: 21888516. DOI: 10.1146/annurev-med-040210-162544

154 Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch RL, Berwick RL, Tourtellot PA, Lippman ME, Byers TE et al: miR-23b overexpression is associated with poor clinical outcome in patients with primary breast cancer. Clin Cancer Res 18: 2791-2799, 2012. PMID: 22272943. DOI: 10.1158/1078-0432.CCR-11-2271

155 Kanasty R, Dorkin JR, Vegas A and Anderson D: Delivery materials for siRNA therapeutics. Nat Mater 12: 967-977, 2013. PMID: 24150415. DOI: 10.1038/nmat3765

156 Wang AZ, Liao Y and Tang L3: MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res 38: 53, 2019. PMID: 30717802. DOI: 10.1186/s13046-019-1059-5

157 Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G and Calin GA: microRNA therapeutics in cancer - an emerging concept. EBioMedicine 12: 34-42, 2016. PMID: 27720213. DOI: 10.1016/j.ebiom.2016.09.017

158 van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmhhat B and Reid G: Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol 18: 1386-1396, 2017. PMID: 28870611. DOI: 10.1016/S1470-2045(17)30621-6

159 Pekarsky Y, Balatti V and Croce CM: miR-15/16-5p as a novel clinical target for hematological malignancies. Carcinogenesis 34: 2-7, 2013. PMID: 23171135. DOI: 10.1093/carcin/bgz183

Received September 1, 2020
Revised October 2, 2020
Accepted October 5, 2020